Diamond Hill Capital, an investment management company, released its “Large Cap Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets exhibited a mixed performance in Q1 as the new presidential administration generated significant buzz with a flurry of actions, leaving investors uncertain about the future direction. The portfolio trailed the Russell 1000 Value Index benchmark in Q1. The strategy returned 1.36% (net) vs 2.14% returns for the index. To get an idea of the fund’s best choices for 2025, check out its top 5 positions. In its first-quarter 2025 investor letter, Diamond Hill Large Cap Fund highlighted stocks such as MetLife, Inc. (NYSE:MET). MetLife, Inc. (NYSE:MET) is a financial services company. The one-month return of MetLife, Inc. (NYSE:MET) was 6.72%, and its shares gained 7.51% of their value over the last 52 weeks. On May 9, 2025, MetLife, Inc. (NYSE:MET) stock closed at $77.85 per share with a market capitalization of $52.26 billion. Diamond Hill Large Cap Fund stated the following regarding MetLife, Inc. (NYSE:MET) in its Q1 2025 investor letter: "As volatility picked up sharply in the quarter, we were active in the portfolio — and we anticipate that as volatility continues into Q2, we will likewise attempt to capitalize on compelling opportunities to reposition the portfolio for the period ahead. In addition to Capital One, among the new positions we initiated in Q1 were MetLife, Inc. (NYSE:MET) and General Mills.Is MetLife Inc. (MET) the Best Health Insurance Stock to Buy in 2025? A closeup of a person reading through a document outlining the advantages of life insurance. MetLife, Inc. (NYSE:MET) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 54 hedge fund portfolios held MetLife, Inc. (NYSE:MET) at the end of the fourth quarter which was 37 in the previous quarter. MetLife, Inc. (NYSE:MET) reported adjusted earnings of $1.3 billion representing an increase of 7% year-over-year. While we acknowledge the potential of MetLife, Inc. (NYSE:MET) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. Story Continues In another article, we covered MetLife, Inc. (NYSE:MET) and shared the list of best insurance stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. View Comments
MetLife (MET): Seizing Opportunities in a Strong Valuation Landscape
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...